Abstract:Although immuno-oncotherapy in clinic has gained great success, the immunosuppressive tumor microenvironment (TME) existing in the "cold" tumor with insufficient and exhausted lymphocytes may result in a lower-than-expected therapeutic efficiency. Therefore, a properly designed synergistic strategy that can effectively turn the "cold" tumor to "hot" should be considered to improve the therapeutic effects of immuno-oncotherapy. Herein, TME-responsive penetrating nanogels (NGs) were developed, which can improve the delivery and penetration of the co-loaded resiquimod (R848) and green tea catechin (EGCG) in tumors by a nano-sized controlled releasing system of the soluble cyclodextrin-drug inclusion complex. Consequently, the NGs effectively promoted the maturation of dendritic cells, stimulated the cytotoxic T lymphocytes (CTLs), and decreased the PD-L1 expression in tumors. The combination of NGs with the OX40 agonist (αOX40) further synergistically enhanced the activation and infiltration of CTLs into the deep tumor and inhibited the suppression effects from the regulatory T cells (Tregs). As a result, an increased ratio of active CTLs to Tregs in tumors (20.66-fold) was achieved with a 91.56% tumor suppression effect, indicating a successful switch of "cold" tumors to "hot" for an immunologically beneficial TME with significantly improved anti-tumor immune therapeutics. This strategy could be tailored to other immuno-oncotherapeutic approaches to solve the urgent efficiency concerns of the checkpoint-based treatment in clinic.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsami.1c08201.Synthesis of HAm, HCD-A, and DMAEP; HPLC spectrum of DMAEP; turbidimetric curves of NGs prepared by HAm16 or HAm61 at pH 7.4 or 6.5; cellular uptake efficiency of EGCG and R848 based on NGs; biochemical stability of natural EGCG in the medium containing FBS; PD-L1 regulation of blank carriers; DC maturation of blank carriers; acute toxicity of E&; in vivo combinational effects of NG-encapsulated EGCG and R848; in vivo anti-tumor experiment for analysis of the immunological profiles; scatter plots of CD11c+CD86+ cells in DLNs, CD11c+CD86+ cells in tumors, CD8+OX40+ in CD3+ cells in tumors, CD8+Ki-67+ in CD3+ cells in tumors, CD45–PD-L1+ tumor cells, FOXP3+OX40+ in CD3+CD4+ cells in tumors, CD8+IFN-γ+ in CD3+ cells in tumors, and CD3+CD8+ T cells in tumors; hydrodynamic diameters and zeta potentials of E& dispersed in various media; and AUC0-t and t1/2 of EGCG and R848 after i.v. administration of E&R and E&, respectively (n = 3) (PDF)This article has not yet been cited by other publications.

A Redox-responsive Prodrug Nanogel of TLR7/8 Agonist for Improved Cancer Immunotherapy

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

Advances in Information Security and Assurance, Third International Conference and Workshops, ISA 2009, Seoul, Korea, June 25-27, 2009. Proceedings

Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

A polyamidoamine (PAMAM) derivative dendrimer with high loading capacity of TLR7/8 agonist for improved cancer immunotherapy

A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy

Regulating Tumor-Associated Macrophage Polarization by Cyclodextrin-Modified PLGA Nanoparticles Loaded with R848 for Treating Colon Cancer

Nanoparticle-enabled concurrent modulation of phagocytosis and repolarization of macrophages for enhanced cancer immunotherapy

Self-Assembled Nanoparticles from the Amphiphilic Prodrug of Resiquimod for Improved Cancer Immunotherapy

Supermolecular nanovehicles co-delivering TLR7/8-agonist and anti-CD47 siRNA for enhanced tumor immunotherapy

Toll-like Receptor-Targeted Nanoparticles: A Powerful Combination for Tumor Immunotherapy

Reinforcing the Combinational Immuno-Oncotherapy of Switching “Cold” Tumor to “Hot” by Responsive Penetrating Nanogels

Repolarizing Tumor-Associated Macrophages and inducing immunogenic cell Death: A targeted liposomal strategy to boost cancer immunotherapy

Site-specific nanoswitch circumventing immune resistance via activating TLR and inhibiting PD-L1/PD-1 axis

Reprogramming Hypoxic Tumor‐associated Macrophages by Nanoglycoclusters for Boosted Cancer Immunotherapy

Nanoreactors with Cascade Catalytic Activity Reprogram the Tumor Microenvironment for Enhanced Immunotherapy by Synchronously Regulating Treg and Macrophage Cells

Nanomaterials Mediated Co‐Stimulation of toll‐like Receptors and CD40 for Antitumor Immunity

Differentiation, metabolic organization, and viability of the visual cell.

Antibody-Decorated Nanoplatform to Reprogram Macrophage and Block Immune Checkpoint LSECtin for Effective Cancer Immunotherapy